Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sihong Zhang

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Computational Intelligence and Neuroscience|January 10, 2022
Application of Optimized GA-BPNN Algorithm in English Teaching Quality Evaluation SystemYaowu Zhu, Junnong Xu, Sihong Zhang
Clinical and Translational Science|February 16, 2026
Prognostic Model-Guided Randomization Improves Efficiency in Early-Phase Trials: Evidence From Surveys and SimulationsSihong Zhang, Justin Zhao, Yanguang Cao
Asian Journal of Surgery|August 4, 2023
Microsurgical treatment for parasagittal meningioma in the central gyrus regionChongjun He, Qiaoshun He, Sihong Zhang, et al.
Frontiers in Psychology|June 20, 2022
The Effect of Brand Internationalization Strategy on Domestic Consumers' Purchase Intention: Configuration Analysis Based on Brand Authenticity PerspectiveShaoqing Zhang, Yue Fang, Yuan Zhang, et al.
Evolutionary Bioinformatics Online|November 4, 2021
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by BioinformaticsXianglai Xu, Yelin Wang, Sihong Zhang, et al.
BMC Urology|January 3, 2024
RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Urologic Oncology|November 3, 2022
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell CarcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Cancer Medicine|March 28, 2024
Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Cancer Medicine|April 9, 2023
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinomaXianglai Xu, Sihong Zhang, Ying Wang, et al.
Scandinavian Journal of Immunology|June 9, 2023
The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibitionJiajun Wang, Sihong Zhang, Ying Wang, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Computational Intelligence and Neuroscience|January 10, 2022
Application of Optimized GA-BPNN Algorithm in English Teaching Quality Evaluation SystemYaowu Zhu, Junnong Xu, Sihong Zhang
Clinical and Translational Science|February 16, 2026
Prognostic Model-Guided Randomization Improves Efficiency in Early-Phase Trials: Evidence From Surveys and SimulationsSihong Zhang, Justin Zhao, Yanguang Cao
Asian Journal of Surgery|August 4, 2023
Microsurgical treatment for parasagittal meningioma in the central gyrus regionChongjun He, Qiaoshun He, Sihong Zhang, et al.
Frontiers in Psychology|June 20, 2022
The Effect of Brand Internationalization Strategy on Domestic Consumers' Purchase Intention: Configuration Analysis Based on Brand Authenticity PerspectiveShaoqing Zhang, Yue Fang, Yuan Zhang, et al.
Evolutionary Bioinformatics Online|November 4, 2021
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by BioinformaticsXianglai Xu, Yelin Wang, Sihong Zhang, et al.
BMC Urology|January 3, 2024
RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Urologic Oncology|November 3, 2022
Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell CarcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Cancer Medicine|March 28, 2024
Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinomaJiajun Wang, Sihong Zhang, Ying Wang, et al.
Cancer Medicine|April 9, 2023
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinomaXianglai Xu, Sihong Zhang, Ying Wang, et al.
Scandinavian Journal of Immunology|June 9, 2023
The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibitionJiajun Wang, Sihong Zhang, Ying Wang, et al.
Pageof 3